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Abstract
Hypertrophic cardiomyopathy (HCM) is defined as left ventricular hypertrophy in the 
absence of abnormal loading conditions. In 50–60% of adolescents and adults with HCM, 
the disease is inherited as an autosomal dominant trait caused by mutations in cardiac 
sarcomere protein genes. The most cases are due to mutations in genes which deter-
mine the synthesis of myosin-binding protein C (MYBPC3) and beta-myosin heavy chain 
(MYH7). More rarely involved genes are those encoding myosin light chain 3 (MYL3), 
tropomyosin alpha-1 chain (TPM1), and cardiac troponins I and T (TNNI3, TNNT2). 
Mutations in genes encoding Z-disc or calcium-handling proteins account for less than 
1% of cases. Multiple sarcomeric protein mutations are present in up to 5% of individu-
als. A further of 5% of patients have inherited metabolic or neuromuscular diseases, 
chromosome abnormalities, and genetic syndromes. HCM is characterized by a highly 
heterogeneous phenotype, highly variable intra- and interfamily expressivity and incom-
plete penetrance, therefore by a genotype-phenotype plasticity.
Keywords: autosomal dominant, mutations, sarcomere proteins genes, incomplete 
penetrance, phenotype
1. Introduction
Hypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease charac-
terized by left ventricular hypertrophy (LVH) in the absence of an underlying systemic condi-
tion or other cardiac disease, such as valvular heart disease or arterial hypertension. HCM is a 
global disease characterized by a prevalence of 1:500 [1, 2]. HCM is the most frequent genetic 
heart disease and the most important etiology of sudden death not due to trauma in adults of 
young age and trained athletes in the United States [3]. The onset of HCM disease can occur at 
any age, from infants to old people, and symptoms usually are not present before teen age in 
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carriers of the specific genetic mutation [3]. HCM is the first autosomal dominant genetically 
transmitted condition, with clinical variability and incomplete penetrance in many cases. 
Clinical picture of HCM covers a large spectrum, from asymptomatic disease to evolving 
heart failure in years and dramatic sudden cardiac death (SCD) triggered by electrical or 
mechanical disorders. The most used tools for diagnosis are cardiac imaging methods, such as 
cardiac echography and magnetic resonance imaging. Asymmetrical hypertrophy involving 
the septum represents a frequent finding [4].
Histopathologic characteristics include myocyte hypertrophy and disarray and increased 
myocardial fibrosis [4], these lesions leading to impaired diastolic function [5]. In ~5–10% of 
patients, cardiac systolic function decreases over time, leading to progressive left ventricle 
(LV) dilatation, heart failure and, finally, burnt-out HCM, morphologically similar to dilated 
cardiomyopathy (DCM) [6].
2. Mechanism of disease
HCM is commonly defined as a sarcomere disease. The variants with pathogenicity were 
found in almost all proteins of the sarcomere [7]. The pathways of molecular alteration are 
augmented actin-activated ATPase activity, fragmentation of interaction between actin and 
myosin and force developing, and modified intramyocyte calcium signaling in cardiac cells 
[8]. Also, some studies found that LVH can be triggered by troubles in CaMKII Mef2 signaling 
pathways and transforming growth factor b (TGF-b) [9].
Phenocopies of HCM are syndromes characterized by multiorgan alteration that can also 
present only LVH or like a dominant trait. These syndromes are storage or metabolic dis-
eases (cardiomyopathies), like Danon disease and Wolff-Parkinson-White syndrome [10], and 
Fabry disease, which is a lysosomal storage condition [11]. These disorders are characterized 
by vacuolar accumulation in the myocytes of glycogen or glycosphingolipids, not by cardio-
myocyte disarray and fibrosis [10]. LVH can also be found in the phenotype of patients with 
Noonan syndrome [12] and Friedreich ataxia [13].
Almost three decades ago, mutations in the beta-myosin heavy chain gene (MYH7) [14] were 
discovered to cause HCM, and since then, hundreds of different disease-causing mutations 
have been identified in genes that encode proteins of the sarcomere, the contractile unit of the 
cell. [15]. This molecular etiology is involved in the most familial diseases [16] and an impor-
tant part of not yet explained hypertrophy sporadically found in childhood and adult age [17, 
18]. There is still need for describing other genetic causes for unexplained LVH transmitted as 
a Mendelian or common trait in the population.
The mechanism of disease is the modification of a unique nucleotide belonging to a protein of 
the sarcomere. Clinical manifestations appear later in life, even if the mutant protein is pres-
ent from birth. Studies on experimental models carrying human HCM mutations uncovered 
the mechanisms of this disease. These models demonstrate typical features of HCM found 
in humans like cell increasing, cardiomyocyte disarray, and interstitial fibrosis clinically 
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evolving similarly with those found in humans: absence of disorder in young people and 
progressive expression of histopathological findings in older age.
3. The genetic background of HCM
Most HCMs are caused by a dominant gene mutation. Half of all descendants of the affected 
individuals will inherit the HCM gene mutation and pose a very high risk for this disease. 
Young carriers of the mutation often have no clinical manifestations, and the symptoms 
develop insidiously, comprising a hypertrophic remodeling that occurs with aging [6]. 
Because HCM have an age-related penetrance, the absence of disease in one assessment can-
not rule out further development. Sequential clinical assessments or genetic testing of family 
members at risk for HCM are very important.
Mutations from 13 single genes cause HCM [15] and represent about 75% of familial HCM [18]. 
Mutations occur predominantly in genes encoding sarcomere proteins [19], the contractile unit 
of myocytes. The typically mutation sarcomere proteins are those of thick and thin filament [20] 
and the less commonly affected are proteins who influence or transmit sarcomere forces (sarco-
mere-associated or Z-disc). Most mutations described in HCM are “private,” appearing only in 
that patient and his family. Families with HCM without any correlation have different mutations 
in most situations [21]. Some mutations are common for specific populations. For example, 4% 
of people with South Asian origin have a unique HCM mutation [22]. For diagnosing the causal 
mutation in every patient, we usually need an accurate sequencing of all HCM genes [23]. This 
issue can be realized through DNA sequencing strategies which are recently developed. The 
HCM genetic diagnosis is possible at several registered molecular diagnostic laboratories, listed 
at the National Center for Biotechnology Information GeneTests website.
Defining the pathogenic mutation in an affected family member allows for further defining 
and low-cost assessing of mutation in all relatives. Mutation carriers have an increased risk of 
developing HCM, while people with negative mutations are at no risk for the disease and do 
not need clinical serial evaluation.
3.1. Mutations in genes that encode sarcomere proteins
Genetic etiology of HCM covers a wide spectrum, existing approximately 900 different muta-
tions reported in the genes that encode 8 sarcomere proteins: the beta-myosin heavy chain 
(MYH7), cardiac myosin C-related protein (MYPBC3), cardiac troponin T (TNNT2), cardiac 
troponin I (TNNI3), cardiac actin (ACTC), alpha-tropomyosin (TPM1), the essential myosin 
light chain (MYL3), and the regulatory myosin light chain (MYL2) [18]. Mutations in MYH7 
and MYPBC3 occur most frequently and represent about 50% of HCM cases. The mutations 
in TNNT2, TNNI3, ACTC, TPM1, MYL3, and MYL2 represent totally less than 20% of HCM 
cases [24]. Mutations within these genes correlate with the disease status in the HCM families 
and are absent from the control populations. Mutations modify highly conserved residues 
throughout evolution, which means that changing each specific amino acid is deleterious—this 
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has been confirmed by animal models that carry mutations in the sarcomeric gene. These 
experimental models develop cardiac remodeling similar to human HCM. Mutations in other 
genes reported as causing HCM are based on weaker evidence for HCM etiology.
Gene encoding for troponin C (TNNC1) represents a sarcomere protein gene that has not been 
definitely involved in HCM [25]. Studies which analyzed over 1000 HCM patients described 
four variants of TNNC1 sequences, although genetic criteria for a pathogenic role remain 
unknown. Experimental models analysis of another gene variant highlighted the augmented 
Ca2+ sensitivity of force transmission and ATPase activation [25, 26], similar to the biophysical 
changes presenting in already defined genes for HCM.
3.2. Mutations in genes encoding Z-disc proteins
Genes encoding molecules that interact with sarcomeric proteins have also been investigated 
for HCM mutations. Many of these analyses focus on proteins located in the Z disc, which 
bind sarcomere units. Other variants have been discovered in genes encoding titin (TTN) [27], 
LIM muscle protein (CSRP) [28, 29], telethonin (TCAP) [30] and myozenin 2 (MYOZ2) [31]. 
Analysis of sequence was referring only to the subsets of the 363 exons encompassing titin, 
which represents a giant molecular structure in the sarcomere laying from the Z-disc to the 
M-line, but the screening for other mutant proteins in the Z-disc is more complete. Functional 
studies of newly identified variants indicate that they alter protein-protein interactions. For 
example, the modified titin residues that have been identified have increased binding affinity 
for actinin [27, 32] or for cardiac ankyrin repeat protein [33]. The pathogenic role of some vari-
ants in HCM remains inconsistent because sequence variants in Z-disc proteins identified in 
some HCM families are not large enough to provide statistically significant analyses.
3.3. Storage cardiomyopathies simulating HCM
Patients with left ventricular hypertrophy (LVH) of unknown etiology and atypical clinical mani-
festations from those with HCM helped identify storage cardiomyopathy and disorders that 
have distinct molecular etiologies. Mutations in the gamma-subunit of the AMP-dependent pro-
tein kinase gene (PRKAG2) cause LVH that is inherited as a dominant feature, in which cardiac 
histopathology shows a marked accumulation of glycogen in myocytes and not myocyte disar-
ray [10]. Patients with PRKAG2 mutations also have electrophysiological disorders and develop 
progressive disease of the conduction system. Mutations in the X-linked lysosome-associated 
membrane protein 2 (LAMP2) cause early and important LVH in boys and male teenagers, severe 
ventricular arrhythmias, and rapid evolution to cardiac failure. LAMP2 mutations demonstrate at 
histopathological examination accumulation of vacuoles filled with non-degraded cellular prod-
ucts resulting from autophagy [10]. Fabry disease is produced by mutations in a gene located on 
X chromosomes, which encodes alpha-galactosidase (GAA). These patients commonly demon-
strate ventricular hypertrophy in addition to systemic involvement. The most patients develop 
myocardial disease [34], while renal, neurological, and cutaneous changes are subclinical.
All these storage cardiomyopathies are accompanied by cardiac hypertrophy. Considering 
histopathological differences with HCM, distinct clinical phenotypes, and different functions 
of mutated molecules, these disorders are considered distinct from HCM.
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4. Clinical gene-related diagnosis of HCM
An important clinical progress resulting from the discovery of the genetic causes of HCM is 
gene-based diagnosis. Given the overlapping clinical phenotype of unexplained LVH that 
arises from various cardiomyopathies and the lack of clinical manifestations to accurately 
predict the implication of a particular HCM gene, gene-based diagnostic platforms required 
the general query of all sarcomere genes, sarcomere-related genes, and genes causing storage 
cardiomyopathies; this technically difficult task is, until recently, very expensive and labori-
ous. With the next-generation sequencing development, many obstacles have diminished.
Contemporary sequencing strategies have the ability to query millions of nucleotides at a 
reasonable cost. An additional advantage is that these platforms define the genetic sequence 
and also the dose of genes. Recent findings indicate that mutations that modify the number of 
gene copies can lead to conditions like congenital heart diseases, neurological and cognitive 
diseases, and neoplasia [35, 36]. A few HCM may appear from an abnormal number of genetic 
copies (by increasing or decreasing the dosage of the gene). The absence of a specific mutation 
in some patients with HCM could be explained by existence of mutations that modulate gene 
dose in HCM and thus a leakage of detection by classical sequencing methods. This concept 
that HCM might be provoked by modified dosage of sarcomere protein genes is particularly 
challenging due to the fact that some mutations in the MYPBC3 gene have been shown to 
cause disease by decreasing protein levels [37, 38]. Another cause of HCM might be mutations 
that modified the quantity of the MYPBC3 gene and perhaps other sarcomere protein genes 
which could significantly affect protein levels.
5. Links between genetic testing and phenotype in HCM
One of the many advances that may result from large-scale genetic testing in HCM is better 
assessment of genotype relevance in the phenotype. HCM genetic testing, recognized to accu-
rately predict disease progression in at-risk relatives, cannot predict the clinical course for 
each patient. It is possible that the number of HCM genotyped patients remains too modest to 
explore these correlations, particularly based on genetic heterogeneity and the influence that 
modifiers such as background genotypes [39], gender [40], and the environment [41]. Clinical 
course is recognized as more adverse in patients with HCM with an identified mutation than 
patients without mutation [42]. Some specific mutations can affect the evolution. Sudden 
cardiac death appears more frequently in MYH7 specific mutations (R403Q, R453C, G716R 
and R719W) [43], and progression to heart failure is more commonly seen in MYH7 (R719W), 
TNNI3 (deletion Lys183), and MYPBC3 (intron 32 mutations deletion) than in other HCM 
mutations [22, 44]. Understanding of the full range of HCM genes together with the molecular 
genetic analysis of well-investigated patient cohorts can contribute to develop these links and 
improve knowledge of clinical differences in HCM.
The age at which the signs and symptoms of HCM appear are influenced by causal gene 
mutation [15, 19]. Clinical manifestations of HCM caused by mutations in the heavy β-myosin 
or troponin T chain usually begin in adolescence [21, 45]. In contrast, myosin-linked protein C 
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mutations, especially those that inhibit the protein, trigger HCM after a prolonged period of 
clinical quiescence that can extend to middle age [46, 47].
The various genetic causes of HCM do not correlate with the size or distribution of hyper-
trophy, with some notable exceptions. Troponin T mutations generally generate much lower 
hypertrophy than other HCM genes, and genetic diagnosis is useful in determining the status 
of individuals at risk of inheriting these mutations [45]. The different morphological mod-
els of HCM hypertrophy (asymmetric, concentric, or apical) do not refer to the underlying 
genotype, except for a single actin mutation that produces uniform apical hypertrophy [48]. 
Factors that involve morphological pattern remain unknown.
The natural history of HCM includes dyspnea and progressive angina. These symptoms 
reflect a noncompliant myocardium, increased ventricular diastolic pressure, and impaired 
diastolic filling [6, 41, 49, 50]. The anatomy of coronary artery tree is normal in HCM but 
mechanism of myocardial ischemia in HCM consists of decrease of blood flow in diastole due 
to intramural arterial remodeling and impaired myocardial relaxation [51]. Approximately 
5% of patients with HCM appear severe diastolic dysfunction which can be accompanied in 
time by contractile insufficiency of the myocardium [52].
Patients with a genetic mutation of the defined sarcomeric protein have lower cardiac output 
than those whose HCM etiology remains unknown [42]. In addition, it was shown that HCM 
specific mutations [53], compound mutations [54], and a mutation that is predominant among 
patients of Indian origin [22] substantially increase the risk of developing heart failure.
6. Cardiac hypertrophy mechanisms in HCM
6.1. Alteration in sarcomere function
Several models have been proposed for mechanisms of myocardial hypertrophy by muta-
tions of the sarcomere genes. Recent analyses in human cardiac samples and experimental 
models show that concentration of myosin-binding protein C is reduced in the myocardium 
of patients with MYBPC3 missense amino acid residues and truncation mutations [37, 38]. 
This information indicates that MYBPC3 haploinsufficiency or a decrease in the quantity of 
functional protein due to a dominant gene mutation that inactivates an allele acts as a patho-
logical mechanism for HCM. In contrast, studies on most other sarcomere mutations indicate 
that these influence on the fact that protein levels are normal, but its function is disturbed. 
The biophysical properties of sarcomeres carrying MYH7 mutations indicate an increase in 
function. Myosines containing HCM mutations improved the ATPase activity of myosines, 
increased the force generated, and accelerated the actin filament gliding [55]. Analyses of 
human TNNT2 mutations indicate that these anomalies show an increase in contraction [56] 
and ATPase activation [57].
The consequences of changes in the biophysical properties of contractile proteins could sig-
nificantly influence sarcomere performance, myocardial cell biology, and myocardial energy. 
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Due to the presence of both mutant and normal proteins within sarcomeres, regulated con-
tractions would become discoordinated, as shown with HCM myosin mutations: HCM muta-
tion MYH7 R403Q is attached to the actin at angles highly variable compared to the normal 
myosin [58]. Biophysical changes of mutant sarcomeres are also expected to modify the cal-
cium cycling and contribute to increased susceptibility to arrhythmia in experimental and 
human HCM [59]. The increase in ATPase activity by sarcomere mutations can also cause a 
higher consumption of myocardial energy, which may accelerate the death of cardiomyocytes 
and may contribute to focal fibrosis and scarring described in HCM [60].
6.2. Activation of Ca2+-dependent signaling in HCM
Dysregulation of intracellular Ca2+, a pivotal modulator of myocardial contraction and relax-
ation, can trigger hypertrophy and failure in this stressed myocardium [61]. Experimental 
models of HCM myocytes exhibit abnormal intracellular Ca2+, including low sarcoplasmic 
reticulum levels and elevated diastolic Ca2+ concentration [56, 62]. In HCM models, Ca2+ dis-
orders precede hypertrophic remodeling. Some longitudinal studies demonstrate that initial 
pharmacological therapy that normalized Ca2+ abnormalities has decreased the development 
of hypertrophy [62]. An important yet unclarified idea raised by this is which hypertrophic 
mechanisms are stimulated by Ca2+ dysregulation in HCM cardiomyocytes?
In experimental studies on hypertrophy induced by pressure overload, intracellular Ca2+ 
triggered activation of calmodulin and calcineurin, its phosphatase, which produce dephos-
phorylation, and activated NFAT (nuclear factor of activated T cell) transcriptional factor, 
a known molecule involved in hypertrophic remodeling [63]. Calcineurin inhibitors, like 
cyclosporin, inhibit hypertrophy induced by overexpression of calcineurin in the hearts [64]. 
However, cyclosporin administered to HCM mice has a very different effect: rapidly evolv-
ing pathological remodeling and cardiac insufficiency [65]. The pathways which provoke the 
stimulation of calcineurin in HCM are not yet understood and some studies have shown a 
critical role for Ca2+-dependent signaling in HCM pathogenesis. These data have promoted 
studies of prevention addressed to normalizing Ca2+ dysregulation in HCM models. Young 
HCM mice (myosin R403Q), without any proof of hypertrophy, were treated with L-channel 
type Ca2+ blocker, diltiazem. This resulted in intracellular Ca2+ levels normalization and 
important inhibition of development of cardiac hypertrophy [62], suggesting that targeting 
key intracellular events in the development of HCM pathology could prevent the develop-
ment of the disease.
6.3. HCM enhances myocyte stress
Modified biophysical forces and intracellular Ca2+ in HCM myocytes, as well as increased 
energy demands, promote increased stress on HCM myocytes. Moreover, microvascular dys-
function, demonstrated by positron emission tomography (PET) and cardiovascular magnetic 
resonance (CMR) in HCM patients [66, 67], may cause ischemia in HCM. In addition, factors 
that increase myocardial stress are supposed to promote death of myocytes and lead to myo-
cardial scarring in HCM [68].
Genetic Evaluation of Hypertrophic Cardiomyopathy
http://dx.doi.org/10.5772/intechopen.79626
35
Molecular analyses also support increased myocyte stress in HCM. In HCM models [69] and 
human HCM hearts, fetal heart genes are found. These genes are normally repressed after 
embryonic development but are re-expressed with myocyte stress [70]. Lipid peroxide lev-
els, indicating oxidative stress, are also elevated in HCM models [71]. Studies of mechanism 
implicated in oxidative stress in HCM hearts exhibit thio-responsive pathways, an observa-
tion that determined the study of N-acetylcysteine in HCM models. High concentration of this 
substance decreased biochemical markers of oxidative stress and surprisingly demonstrated 
the reversal of fibrosis in HCM models [60, 72]. The potential favorable effect of antioxidants 
in human HCM requires further studies.
7. Clinical testing and genetic etiology
Pathogenic variants for HCM were originally described in eight genes encoding sarcomere 
proteins, with most (~80%) present in the MYH7 and MYBPC3 genes [3, 73]. Typically for 
these structural proteins, most sarcomere variants act in a dominant negative way (by nega-
tively affecting the normal gene product). Loss-of-function variants that lead to haploinsuf-
ficiency appear less frequently, predominantly in the MYBPC3 gene [74]. Sarcomeric variants 
are identified in up to 60% of HCM patients with a family history and in approximately 40% of 
patients with sporadic HCM [75]. Storage cardiomyopathies that mimic HCM are caused by 
mutations in GLA (Fabry disease), LAMP2 (Danon disease), and PRKAG2 (Wolff-Parkinson-
White syndrome).
The HCM-associated gene spectrum has been developed in nonarrhythmic genes and 
includes genes encoding Z-disc proteins and proteins localized in the plasma membrane 
and sarcoplasmic reticulum. Variants in these genes are rare, with limited studies sup-
porting evidence of a role in the disease. Some genes are associated with strong genetic 
evidence such as segregation with disease or functional data in vivo (e.g. CSRP3) [29], 
but many genes (e.g. MYH6, MYLK2, and TCAP) are only supported by the presence of 
variants in affected individuals and the absence from controls. These genes are better con-
sidered candidate genes. Almost 1000 HCM variants have been diagnosed so far [75], most 
of which being unique or private, and can only be identified through a comprehensive 
genetic evaluation. A small number of recurrent variants are detected at larger population 
frequencies; the most frequent being a 25 bp deletion in the intron 32 of MYBPC3 gene, 
which is predominant in Southeast Asian populations (~4%) and increases risk of heart 
failure with an odds ratio of ~7 [45].
With few exceptions, genotype-phenotype correlations for HCM are incompletely defined. 
Some, but not all, TNNT2 mutations are associated only with minor hypertrophy, but with an 
appreciable risk of arrhythmia [45]. MYH7 variants generally appear to promote significant 
LVH that is evident in the second decade of life and are believed to be associated with an 
increased risk of heart failure and SCD [76]. Pathogenic variants in MYBPC3 are believed 
to be associated with a later onset [47]. These variants were also identified in a significant 
proportion of patients with early onset LVH in childhood [18]. Most variants of MYBPC3 in 
the pediatric population were missense mutations that contrasted with the high prevalence of 
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identified loss-of-function variants in HCM adult patients and suggest that missense variants 
may have worse functional consequences [18].
The US HCM Guidelines recommend complete testing for five HCM genes (MYBPC3, MYH7, 
TNNI3, TNNT2, and TPM1) [77]. Sequencing diagnostic panels, including these genes, are 
offered by several laboratories around the world.
In fact, genetic testing for HCM is mainly used to identify families with a detectable genetic 
cause of the disease and to examine family members at risk. Testing can also help to exclude 
nongenetic conditions, such as the heart of the athlete, though in case of an identification 
of a pathogenic variant [75, 78]. Due to the absence of clear genotype-phenotype links, the 
genetic test results in clinical management guidance have limited usefulness. The exception 
is enzyme replacement treatment for storage diseases that may have isolated LVH [79, 80].
An area under development is the use of genotype analysis to guide treatment decisions in 
preclinical HCM patients. Experimental animal studies suggest that some calcium channel 
blockers, such as diltiazem, may influence by delaying the clinical progression of HCM [62].
Studies in animals have also led to a link between sarcomeric HCM and increase in transform-
ing growth factor b signaling. An anti-transforming growth factor b antibody and losartan 
(a type 1 angiotensin II receptor antagonist) prevented cardiac fibrosis and hypertrophy in 
sarcomere mutation-positive mice, which may suggest additional therapeutic possibilities [9].
Since the discovery that pathogenic variants in sarcomeric genes cause HCM [7], much prog-
ress has been made to define the genetic etiology of inherited cardiomyopathies. The high risk 
of SCD in patients with this disorder has encouraged interest in clinical genetic testing. All 
cardiomyopathies are characterized by a high heterogeneity linked to the great number of loci 
and allele that require sequential analysis of the entire coding region of several genes, which 
has been an expensive and long-lasting process using classical technologies. Genetic and 
phenotypic overlapping between different cardiomyopathies is increasing and this assumes 
more difficulties, often leading to testing more cardiomyopathy-specific gene panels when 
the diagnosis is not entirely known. The next-generation sequencing technologies (NGS) 
have eliminated these problems and allowed the concomitant investigation of a multitude of 
genes. A negative effect of this possibility of sequencing any gene is an increased likelihood of 
detecting variants of unclear clinical significance (VUSs). This disadvantage requiring a strict 
review of the proofs supporting the signs of disorder association as variants in poorly studied 
genes can be difficult to estimate. There were described variants in >50 genes to be causal for 
various inherited cardiac muscle diseases, but a comprehensive review shows that only half 
of them meet the criteria to be considered a definitive gene of the disease.
Current practice guidelines and expert opinions on clinical approach and genetic diagnosis for 
inherited cardiomyopathies recommend taking a detailed family history that includes at least 
three generations, clinical screening of at-risk family members, counseling patients about the 
possibility of an inherited cause, and examining by genetic testing the most obvious affected 
persons in the family [77]. The recommendations of specific or comprehensive genetic testing 
are established by the guidelines for only a small number of genes [77], in opposition to the 
growing use of large gene panels in clinical practice.
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For inherited cardiomyopathies, the treatment possibilities are very few and the clinical util-
ity of genetic testing is based on the capacity to confirm the etiology of the disease in proband 
(when a known pathogenic variant is identified). Subsequent genetic testing of at-risk family 
members can eliminate the risk of disease (when negative) or identify those members who 
require monitoring or clinical intervention to reduce the risk of morbidity or mortality (when 
positive). The spectrum of pathogenic variants present in the population is incompletely char-
acterized, even in well-known disease genes, with a high probability of detecting a new VUS 
sequence that can create emotional stress for patients [80].
8. Genotype-phenotype overlap between inherited 
cardiomyopathies
Cardiomyopathies were classically classified only based on clinical features, including ven-
tricular morphology and function. Although HCM, DCM, and arrhythmogenic right ventric-
ular cardiomyopathy (ARVC) are distinct clinical diseases, there is an increasing observation 
of substantial genetic and phenotypic overlapping. There are phenotypic overlaps between 
HCM in the final stage and DCM [81] and between DCM and ARVC (which may be mani-
fested by ventricular dilatation and VS involvement) [82]. Also, left ventricular noncompac-
tion (LVNC) features may overlap with those of HCM, DCM, and restrictive cardiomyopathy 
(RCM) [83].
The genetic etiologies underlying these conditions are clarified and the overlapping results 
increase substantially. Pathogenic sarcomere variants have been identified first in HCM 
patients, but also in patients with DCM, LVNC, and RCM [80].
Z-disc mutation genes were involved in DCM and HCM [84]. Desmosomal protein genes 
were originally thought to be involved only in ARVC, and the evidence suggests that variants 
in these genes can also lead to DCM [85]. The phenotypic spectrum of variants in the desmin 
gene includes DCM, RCM, and, most recently described, ARVC [86–88]. Variants of the car-
diac troponin T (TTN) gene have recently been shown to be a frequent etiology of DCM, but 
growing evidence also associates this gene with ARVC [89].
Although it is established that variants in a particular gene may lead to more than one cardio-
myopathy, it has been investigated whether the responsible variants are different. Some stud-
ies have discovered the same variant in patients with HCM and in patients with DCM, this 
fact being attributed to phenotypic plasticity [90, 91]. However, the background molecular 
mechanisms of HCM (high contractility) and DCM (low contractility) are extremely differ-
ent, which raises questions as to whether the same variant can indeed cause both diseases 
[80]. Functional characterization of several HCM and DCM variants revealed opposite funda-
mental properties, supporting distinct variants [92–94]. Assuming nonoverlapping variants, 
identification of HCM variants in patients with marked LV dilatation and impaired systolic 
function may reflect remodeling in the final phase of HCM rather than primary DCM. Another 
explanation for identifying one and the same variant in disorders with distinct molecular 
mechanisms is that they are not the principal or initial cause of the disease but act as modifiers 
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or are completely benign. We have now the possibility to evaluate the spectrum of rare benign 
variations since we are able to query thousands of sequenced genomes and exomes (1000 
Genomes Project, National Heart, Lung and Blood Institute Exome Sequencing Project). A 
disadvantage was the fact that many studies in the past have inferred gene pathogenicity 
based on insufficient proofs. This has recently been demonstrated for a lot of published vari-
ants that have been reported to determine DCM [95]. One example illustrating the temporal 
evolution of a variant is the Ala833Thr variant of MYBPC3, which was originally reported 
in four HCM probands and 1 in 400 control individuals [74, 96, 97]. Its presence in a single 
control person was considered insufficient to exclude a pathogenic role because low penetra-
tion is quite frequent in HCM. It is already discovered that this variant is present in 12 of 6952 
chromosomes (0.17% Exome Sequencing Project from the Heart, Lung and Blood National 
Institute), demonstrating the importance of extensive genomic sequencing studies and clearly 
suggesting that there is a low probability for this variant to be a primary cause of HCM.
In conclusion, it seems probably that the individual variants are most commonly specific to 
one cardiomyopathy presentation, and new studies that include more precise phenotypic test-
ing and classification of the genetic variants can be useful to prove this with certainty (Table 1).
Gene Location Inheritance Muscular component Gene product
MYH7 14q11.2 AD Thick filament β-Myosin heavy chain
MYL3 3p21.31 AD Thick filament Essential myosin light chain
MYL2 12q24.11 AD Thick filament Regulatory myosin light chain
TTN 2q31.2 AD Thick filament Titin
MYH6 14q11.2 AD Thick filament α-Myosin heavy chain
TNNT2 1q32.1 AD Thin filament Cardiac troponin T
TNNC1 3p21.1 AD Thin filament Cardiac troponin C
TNNI3 19q13.42 AD Thin filament Cardiac troponin I
ACTC AD Thin filament α-Cardiac actin
TPM1 15q22.2 AD Thin filament α-Tropomyosin
MYBPC3 11p11.2 AD Intermediate filament Cardiac myosin-binding protein C
CASQ2 1p13.1 AR Calcium handling Calsequestrin
JPH2 20q13.12 AD Calcium handling Junctophilin 2
MYOZ2 4q26 AD Z-disc Myozenin2
ACTN2 1q43 AD Z-disc α-Actinin2
VCL 10q22.2 AD Z-disc Vinculin/metavinculin
TCAP 17q12 AR, AD Z-disc Telethonin
CSRP3 11p15.1 AD Z-disc Muscle LIM protein
Table 1. Genes having pathogenicity for hypertrophic cardiomyopathy [98–100].
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9. Conclusions
For an optimal approach of patients with HCM, genetic testing is available and very useful. 
Major progresses have been made with the finding of several mutations that have demon-
strated marked genotypic and phenotypic heterogeneity of this cardiac muscle disorder. This 
genetic testing must be performed in certified diagnostic laboratories. The first indication 
is for testing patients who have completed the diagnostic criteria for HCM, allowing fur-
ther screening of the family members. Some other potential advantages are confirming or 
infirming the diagnosis in ambiguous situations and allowing a better understanding of this 
polymorphic disease.
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